With eight years of experience in bioinformatics and biostatistics, I began my career as an alternative-military researcher at CorestemChemOn Co., Ltd. I integrate multi-omics datasets to evaluate the efficacy of cell-based therapies for refractory diseases and support clinical statistics and trial design.
.
Research Scientist, Rheumatology Research Laboratory β Hanyang University Medical Center
2025.2 - Present
β’ Apply next-generation sequencing and integrated multi-omics analytics to unravel the pathogenic mechanisms of rheumatic diseases.
β’ Discover novel genetic variants and biomarkers, providing the scientific foundation for next-generation precision-medicine therapies.
Bioinformatics & Biostatistics Researcher- Corestem ChemOn Co., Ltd.
2019.7 - 2025.1
β’ Assess therapeutic efficacy of cell-based treatments by analysing bulk RNA-seq, single-cell RNA-seq and other multi-omics data in lupus, ALS, spinocerebellar ataxia, and more.
β’ Lead biomarker discovery using WGCNA and other network approaches, integrating clinical endpoints.
β’ Provide statistical analysis and clinical-trial design support; authored all statistical sections for MFDS & FDA submissions of the Phase III Neuronata-R trial.
β’ Administer on-premises Linux servers, NAS storage and a dedicated GitHub organisation for the Bioinformatics team.
Linux Master Level 2
2016.03
[Ph.D. Candidate] Kyung Hee University, Dept. of Biology β Immunogenomics Laboratory
GPA : 4.3 / 4.3, 2023.3 - νμ¬
[M.Sc. Biology] Kyung Hee University, Dept. of Biology β Immunogenomics Laboratory
GPA : 4.2 / 4.3, 2017.9 - 2019.06
[B.Sc. Biology] Kyung Hee University
GPA : 4.0 / 4.3, 2013.3 - 2017.02
Academic Excellence Scholarships (Undergrad & Grad)
2013.09 - 2015.02, 2017.09 - 2019.06
Kwanjeong Educational Foundation Scholar
2015.03 - 2017.02
English
TOEIC Speaking LV 6 / 2020.11
Japanese
JLPT N3 / 2025.07
Member, Biology Academic Society βCell,β Kyung Hee University
2013.3 - 2016.02
Proficiency is grouped into Advanced Β· Intermediate levels.
Hard Skills
Soft Skills
Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans